drugset / Trial / NCT06095089
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of Parts 1, 2A, and 2B of the study is to determine the recommended regimen for Phase 2 (RP2Rs) of combination of JNJ-87189401 with JNJ-78278343 and the purpose of Part 2C of this study is to determine how safe the RP2R(s) of the combination of JNJ-87189401 and JNJ-78278343 is, with or without apalutamide. Part 3 of this study evaluates the safety of the triplet combination of JNJ-87189401 and JNJ-78278343 with standard of care (SOC) lutetium Lu-177 vipivotide tetraxetan. Part 4 of this study further evaluates the safety of the triplet combination of JNJ-87189401 and JNJ-78278343 with JNJ-101556143 in participants with advanced prostate cancer.
Timeline
- Start
- 2023-11-01
- Primary completion
- 2027-06-21
- Completion
- 2028-06-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Apalutamide | Small molecule | — | — |
| Subject | JNJ-101556143 | Unknown | — | — |
| Subject | JNJ-87189401 | Unknown | — | — |
| Subject | Pasritamig | Other / unclassified | — | — |
| Background | 177Lu-PSMA-617 | Other / unclassified | — | — |